These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 18695919)

  • 1. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Ohge H; Sueda T
    J Gastrointest Surg; 2009 Jan; 13(1):85-92. PubMed ID: 18704593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
    Kurosaki I; Hatakeyama K
    Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
    JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
    Takano S; Togawa A; Yoshitomi H; Shida T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Tomonaga T; Nomura F; Miyazaki M
    Ann Surg Oncol; 2008 Nov; 15(11):3157-68. PubMed ID: 18712570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
    Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
    BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
    Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
    World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
    McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
    J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer.
    Nakamura M; Kayashima T; Fujiwara K; Nagayoshi Y; Kono H; Ohtsuka T; Takahata S; Mizumoto K; Tanaka M
    Hepatogastroenterology; 2013; 60(122):354-7. PubMed ID: 23574657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
    Aoyama T; Yamamoto N; Kamiya M; Murakawa M; Tamagawa H; Sawazaki S; Numata M; Kobayashi S; Ueno M; Morimoto M; Shiozawa M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S116-S121. PubMed ID: 33380664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
    Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.